New, highly experienced team members with a lot of passion, enthusiasm and drive have joined our growing Glycanostics team
We are happy to announce that our team is growing. Warm welcome to our R&D, marketing, business development, HR and office admin team members! We are looking forward to build together a world, where cancer will be diagnosed early and treated successfully.
Glycanostics have been awarded a Seal of Excellence under the EIC Transition scheme to continue with its development of diagnostic tests for breast, lung and pancreatic cancers
Applications that meet all the criteria but are not recommended for funding due to budget limitations will be awarded a Seal of Excellence to help them secure funding from other sources. Companies with a Seal of Excellence can also gain support from EIC Business Acceleration Services. EIC Transition. The EIC Accelerator is a European Innovation […]
Glycanostics receives prestigious EIC Accelerator grant
Glycanostics has been selected as one of 65 innovative start-ups and SMEs out of more than 4,000 applicants to receive funding under the European Innovation Council (EIC) Accelerator scheme. Glycanostics became the third company in the history of Slovakia to receive an EIC Accelerator grant, with grant funding amounting to €2 million and potential direct equity […]
Glycanostics was successful on Crowdberry Investment Platform
Another important milestone achieved by the Glycanostics team! Via the Crowdberry Investment Platform, we presented our highly accurate diagnostic test to private investors in September 2021 and raised an additional investment of €690,000. With the help of our investors we can now be strong players in innovation processes and drive healthcare transformation in diagnostics in […]
Glycanostics meets the President of the EC, Ms. Ursula von der Leyen
On Monday 21st June , our CEO Eva Kováčová (on the right) together with CSO Jan Tkac (on the left) had the great honour to introduce the company Glycanostics to the President of the EC, Ursula von der Leyen, our Prime Minister Eduard Heger and the Vice-President of the EC, Maroš Šefčovič. As one out of seven selected innovative companies, we presented our […]
Important step for Glycanostics with CBIM
Glycanostics and Crowdberry Investment Management took an important step towards achieving its vision. On Friday 7th May 2021 we signed an investment agreement to gain key resources of €310,000 for Glycanostics. Crowdberry’s Investment significantly accelerated our strong effort to save many lives across the world via our non-invasive Prostate Cancer Diagnostic Test. The Crowdberry investment […]
Eva Kovacova joins Glycanostics as CEO as of January 2021
We are pleased to announce that Eva Kovacova joined Glycanostics as our CEO as of January 2021. Eva worked more than 18 years for some of the largest pharmaceutical companies as Director Corporate Development, as well as Finance Director. She was member of the team that secured signing of 3-arm transaction between GSK and Novartis […]
A HIGHLY-PRESTIGIOUS AWARD FOR A GLYCANOSTICS CO-FOUNDER
This year, a well-established IT company from Slovakia ESET launched a prestigious ESET Science Award for exceptional scientists to increase the popularity of excellent scientists. Among all the scientists nominated, the winner of the main category and recipient of 100 000 € became Jan Tkac, CSO and co-founder of the Glycanostics company. All finalists were […]
INTERNATIONAL PATENT APPLICATION NO. PCT/EP2019/057386
On 3rdOctober 2019, PCT application titled “Means and methods for glycoprofiling of aprotein” (applicant Glycanostics, inventors Tomas Bertok and Jan Tkac) waspublished under publication number WO 2019/185515. This patent applicationcovers the main principles and company´s IP used during the diagnostic assaydevelopment. Patent abstract: Thepresent invention provides magnetic carriers, anti-glycoprotein antibodies, theantigen binding portions thereof, one or […]
